2Coco F L, Diverio D, Falini B, et al. Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia[J]. Blood, 1999, 94(1): 12.
3Robert E G, Cheryl L W, James L S, et al. Association of PML-RAR Fusion mRNA Type With Pretreatment Hematologic Characteristics But Not Treatment Outcome in Acute Promyelocytic Leukemia: An Intergroup Molecular Study[J ].Blood, 1997, 90( 4): 1656.
4Jurcic J G, Nimer S D, Scheinberg D A, et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukenaia[J]. Blood, 2001, 98(9): 2651.
5Pollock J L, Westervelt P, Kurichety A K, et al. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARa-driven acute promyelocytic leukemia[J]. PNAS, 1999,96(26) : 15103.
6Huang W, Sun G L, Li X S, et al. Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse[J]. Blood, 1993,82(4) : 1264.
7Morschhauser F, Cayuela J M, Martini S, et al. Evaluation of Minimal Residual Disease Using Reverse-Transcription Polymerase Chain Reaction in t(8; 21 ) Acute Myeloid Leukemia:A Multicenter Study of 51 Patients[J ]. Journal of Clinical Oncology, 2000, 18(4): 788.
